To create the society without people left behind

In an aging society with a declining birthrate, it is important not only to extend healthy life expectancy, but also to maintain the number of healthy children. We try to solve the problems of both pediatric and aging diseases.

Developing novel medicines
targeting ferroptosis / oxidized lipid

FELIQS【fíːlɪks】 is a preclinical-stage start-up company established based on the robust science from molecular pathobiology, department of pharmaceutical science, Kyushu university.

Ferroptosis is a new type of cell death reported in 2012(Cell. 2012 May 25;149(5):1060-72.), and it is caused by the accumulation of oxidized lipids. In recent years, it has been reported to be associated with many diseases such as cancer, ischemia-reperfusion injury, and neurodegenerative diseases, and is being investigated as a new drug target. We have established a unique drug discovery platform targeting ferrotosis/oxidized lipids, and are now conducting preclinical research toward the clinical trial to create new medicine for unmet medical needs in ophthalmology space.

FELIQS EXPANDED ACCESS POLICY

Name

FELIQS CORPORATION

Address

1-1 Hyakunenkoen, Kurume, Fukuoka, 8390864, JAPAN

US Office

JLABS@NYC 101 6th Ave 3rd floor, New York, NY 10013, U.S.A

Capital

675,500,000 JPY

Main bank

MUFG bank

Pipeline

Feel free to write down your inquiry in the following form.

Please enter here to input your inquiries